10 May 2021 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has announced today that it has accepted four new medicines for routine use.

Encorafenib (Braftovi) was accepted for use in combination with the medicine cetuximab for the treatment of colorectal cancer (cancer of the large bowel or rectum) in patients with a gene mutation called 'BRAF V600'.

Ravulizumab (Ultomiris) was accepted for the treatment of atypical haemolytic uraemic syndrome, a rare, life threatening disease that causes abnormal blood clotting in small blood vessels and the breakdown of red blood cells resulting in kidney failure.

Read SMC press release